[Webinar] How to better optimize an oncology drug discovery program
Register for this webinar discussing how conventional and innovative integrated technological skills should be incorporated into an oncology program.Read more
After gaining a PhD in pharmacology from the University of Dijon, Philippe Genne began his scientific career as a project leader at Debiopharm where he oversaw a clinical development program related to multi-drug resistance inhibitors. He also worked as a research associate at Glaxo-Welcome.
His preclinical research experience in oncology also encompasses phase I and phase II clinical trials in conjunction with Inserm. In 1995, he founded Oncodesign in Dijon. Over the past 18 years, he has earned a reputation as a serial entrepreneur in life sciences. As well as being Chairman of Oncodesign, a company specialized in the discovery of new therapies and European leader in the preclinical evaluation of anti-cancer therapies, he is also Chairman of the Pharmimage platform, which he set up in 2008. Philippe Genne is well known for his activities right across the life sciences value chain. In 2012, he helped set up the French association of life sciences service and innovation companies (AFSSI). He is the Vice-President of the SMEs College at Medicen.
Oncodesign is a biopharmaceutical company dedicated to precision medicine, founded in 1995 by its current CEO and majority shareholder, and has been listed on Euronext Growth Market since April 2014. Its mission is the discovery of effective therapies to fight cancer and other diseases without therapeutic solutions. With its unique experience acquired by working with more than 1000 clients, including the world’s largest pharmaceutical companies, along with its unique technological platform combining Artificial Intelligence, state-of-the-art medicinal chemistry, pharmacology, regulated bioanalysis, medical imaging, Oncodesign is able to select new therapeutic targets, design and develop potential preclinical candidates through to clinical phases. Oncodesign has configured its organization to offer innovative services to its customers and to license its proprietary molecules. Applied to kinase inhibitors, which represent a market estimated at over $65 billion by 2027 and accounting for almost 25% of the pharmaceutical industry’s R&D expenditure, Oncodesign’s technology has already enabled the targeting of several promising molecules with substantial therapeutic potential, in oncology and elsewhere, along with partnerships with global pharmaceutical groups. Oncodesign is based in Dijon, France, in the heart of the town’s university and hospital hub, and within the Paris-Saclay cluster. Oncodesign has 230 employees within 3 Business Units (BU): Service, Biotech, Artificial Intelligence and subsidiaries in Canada and the USA.
Philippe Genne | CEO
Tel. : +33 (0)380 788 260
Mathilde Bohin / Louis-Victor Delouvrier
Tel. : +33 (0)144 719 495
Tel. : +33 (0)144 710 015